Study in a well-accepted mouse model of severe Tuberous Sclerosis Complex (TSC) showed that simufilam attenuated the progression of seizures in a dose-dependent manner Results confirm and extend ...
(MENAFN- GlobeNewsWire - Nasdaq) As previously disclosed, the studies did not meet pre-specified co-primary, secondary, or exploratory biomarker endpoints The paper provides a detailed analysis of the ...
AUSTIN, Texas, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for ...
Cassava Sciences, Inc. (NASDAQ:SAVA) announced that the U.S. Food and Drug Administration has placed a full clinical hold on the company’s proposed proof-of-concept clinical trial of simufilam for ...
Findings showed no significant reduction in cognitive or functional decline with simufilam when compared with placebo. Topline results were announced from a phase 3 trial evaluating simufilam, an oral ...
Cassava Sciences Inc. (NASDAQ:SAVA) on Tuesday shared topline results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate Alzheimer’s disease. REFOCUS-ALZ randomized approximately ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results